Supraventricular arrhythmias are common in Brugada syndrome (BS), and notoriously difficult to manage with medical therapy secondary to associated risks. Pulmonary vein isolation (PVI) is often utilized instead, but its outcomes in this population are not well-known. We aim to provide a holistic evaluation of inter- -
| INTRODUCTION
Approximately 20% of patients with Brugada syndrome (BS) develop supraventricular arrhythmias. 1 Atrial fibrillation (AF) in particular comprises 10%-20%. [2] [3] [4] Medical antiarrhythmic therapy in those patients is particularly challenging because some drugs may increase the risk of sudden cardiac death in BS. Moreover, the presence of AF concomitantly with BS and an implantable cardioverter-defibrillator (ICD) often leads to inappropriate shock. 5 Pulmonary vein isolation (PVI) is an effective method for controlling paroxysmal AF 6 by electrically isolating the pulmonary veins (PVs) from the left atrium (LA). PV isolation often eliminates the need for antiarrhythmic drugs, and may therefore provide a uniquely attractive treatment modality for AF in patients with BS.
However, the efficacy of PV isolation is unknown in this patient population. Only small series of patients have been published so far, and as such, the utility of the technique in BS remains undetermined.
The present study sought to provide a holistic evaluation of 
| ME TH ODS
A systematic review and best-evidence synthesis was conducted in compliance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. 
| Literature search
Electronic databases Medline, Embase, Cinahl, Cochrane, and Scopus were systematically searched for publications between 01/01/1995 and 12/31/2017. The following search terms were used: "atrial fibrillation ablation in Brugada syndrome"; "pulmonary vein isolation in Brugada syndrome"; "atrial fibrillation in patients with Brugada syndrome"; "catheter ablation of atrial tachyarrhythmias". Each article's references were screened for additional relevant papers that may have been missed by the initial search.
| Eligibility criteria
Titles and abstracts were screened for eligibility via the following criteria.
| Inclusion
• Languages: English, French, Swedish, Arabic, Norwegian, Danish, and Spanish.
• Publication type: Original manuscripts in peer-reviewed journals.
• Study design: Systematic reviews, meta-analyses, randomized-controlled trials (RCTs), case-control and cohort studies. Studies reporting adequate follow-up information were included.
• Study population: Human participants of all ages who have BS, AF and have undergone pulmonary vein isolation.
• Study outcomes: Acute success, complication rates, and long-term follow-up.
| Exclusion
• Study design: Nonsystematic reviews, cadaveric, biomechanical, and laboratory studies. Patient overlap between two included studies; aka efforts were made to ensure that no patient's data was included twice.
• Study population: Animals.
| Screening
Initially, one reviewer read all titles retrieved from the database search and removed citations clearly unrelated to AF ablation in BS.
Subsequently, an abstract review was carried out. Full-text articles were obtained for all abstracts except those that clearly did not meet the eligibility criteria. If after analysing the full text, the eligibility of an article remained uncertain, a second reviewer conducted a full-text analysis of the article to determine eligibility. A third reviewer was consulted in the event of disagreement. Level of agreement on study eligibility was tested using the kappa statistic and 95% confidence interval.
| Critical appraisal
Two reviewers appraised eligible papers using the modified Scottish
Intercollegiate Guidelines Network (SIGN) criteria. 8 Reviewers were international scientists and/or had experience in systematic review methodology. characteristics; (ix) preprocedural work-up; (x) electrophysiological details of the PV isolation; (xi) prognostic factors/outcomes; (xii) complications; (xiii) follow-up periods, and (xiv) key findings. These endpoints were summarized in two tables (Tables 1 and 2 ).
| Data extraction

| Statistical analysis
Categorical data are presented as numbers (n) and percentages, as well as a range from minimal up to maximal reported values, with a corresponding grouped median. Continuous data are expressed as mean and standard deviation.
| RESULTS
| Demographic characteristics
A total of 49 patients from four different studies were included in the analysis 9-13 ( 
| Follow-up and endpoint definition
In all studies, clinical follow-up consisted of physical examination, ECG and a minimum duration of 24 hours of holter recording. These parameters were assessed at 3, 6, and 12 months post-op, as well as every 6 months after the first year. Follow-up of ICD data was performed every 6 months in the outpatient clinic in all studies. None of the studies mentioned the use of remote device monitoring.
Recurrence of an atrial arrhythmia was defined as an episode of an atrial arrhythmia lasting >30 s. system. The endpoint of the PV isolation was either the elimination or dissociation of the PV potentials recorded from the circular catheters placed within the PVs and exit block from the PVs. In all included series, after the map was completed, radiofrequency (RF) energy was applied through a 3.5 mm irrigated tip ablation catheter in a power- 
| DISCUSSION
The main findings of the study are: (i) freedom from AF recurrence in patients with BS and paroxysmal AF after PV isolation (by means of RFA or CB technology) is high; (ii) PVI often obviates the need for AADs after intervention; (iii) ablation decreases the incidence of inappropriate ICD intervention for AF; (iv) major intervention-related complications are rare.
| Background
Previous studies have demonstrated that the index of atrial conduction abnormalities and atrial arrhythmogenesis are substantiated in BS. [13] [14] [15] A shorter action potential duration and steeper restitution curve in the setting of a shorter diastolic interval are observed.
These disparities are thought to relate to the smaller late sodium current 13 or greater transient outward potassium current 16 as compared to the normal heart.
The incidence of AF in patients with BS is high. [2] [3] [4] Both shortening of refractoriness and conduction delay may be critical in AF induction. Results from previous studies and the present findings suggest that triggers coming from PVs play an important role in the genesis of AF in these patients. 17 Phase 2 re-entry may also be contributing to its development. Of note, the onset of AF in patients with BS is often preceded by fluctuations in autonomic tone, commonly during the night. 15 An increased vagal tone may reduce atrial conduction velocities and shorten the effective refractory period, leading to the induction of AF.
It is well known that the clinical management of AF in patients with BS is challenging. The use of sodium channel blockers confers risk owing to their potential proarrhythmic effects, including fatal ventricular arrhythmia. In addition, the safety of drug use, other than quinidine 18, 19 and bepridil 20 in BrS has not been clearly investigated, especially when used for treatment of AF. In fact, the vast majority of patients herein included were not previously maintained on AADs, underlining physicians' reluctance to prescribe AADs in this setting.
| Procedural success
PVI is commonly utilized for treatment of refractory AF. The literature indicates that in the normal AF population, a 79.8% long-term success rate is observed. 21 There is wide variability, however, and success for PAF may be higher. Our data point to high success rates of PVI in BS as well. Through multiple PVI procedures instituted as clinically indicated, the combined BS population successfully achieved a 91.8% remission rate during long-term follow-up. As such, and in light of the substantial risks of AADs in this population, PVI provides a reliable and appealing alternative.
| Temporal trends
Studies included within this analysis span from 2008 11 through 2017. 10 During this time, a shift in available technology and insight into AF ablation has occurred. As such, advancements during this time period could have baring on procedural results. Moreover, we have seen an evolution of the preferred procedural protocol to include nonfluorscopic 3-dimensional mapping or CB. However, although based on a limited number of patients, there does not appear to be significant differences in outcomes between the first study published in 2008 11 and the last in 2017. 10 Nevertheless, quantitative data must be contextualized to the available technology with which it was derived before clinically relevant conclusions can be drawn regarding variations of success over time.
| Adjunctive effects
Many patients with BS are implanted with ICDs. Programming a single VF zone above 210 to 220 bpm is sometimes suggested. 22 Inappropriate shocks resulting from atrial tachyarrhythmias remain common, and can be highly problematic for these patients. In fact, more than 40% of the patients included in this study suffered inappropriate shocks for rapid AF. Remarkably, none presented shocks after ablation, irrespective of whether remission had been successfully achieved. As such, AF ablation offers a useful approach to prevent inappropriate shocks.
| Complications
As is demonstrated in our patient population, the rate of major complications secondary to PVI in experienced centers has become minimal. As the BS population is subject to higher than normal complication rates from AADs, and as this population is relatively younger than the average AF population, procedural risks may prove lower than those of medical therapy. An individual assessment of each BS patient's risks from PVI must be undertaken in light of these data, and utilized to guide clinical decision-making.
| Limitations
The present study has several limitations that must be acknowl- 
| CONCLUSION
The results of the present study indicate that AF ablation achieves acute and long-term success in the vast majority of patients. Moreover, it is effective in preventing inappropriate ICD therapy secondary to rapid AF. Complication rates of PVI in BS are low. These results suggest that, in light of the risks of AADs and risk of inappropriate ICD shocks in the BS population, catheter ablation could represent an appropriate first-line therapy for PAF in BS patients.
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